Resumen
- Objective: To evaluate the immunogenicity of Hepavax-Gene recombinant hepatitis B vaccine in INML workers since the last administered doses. Methods: Cross-sectional study on 603 health workers with at least three administered recombinant vaccine doses. Antibody levels (anti-HBs) were measured using the ELISA technique during December 2000 and January 2001, taking into account that the last dose in the vaccination varied between 1 and 6 years. Results: A total of 344 men and 259 women with an age mean of 38.8±7.3 years were studied. Protection levels were found in 90.7% (≥10 U/1), decreasing significantly with the worker's age (p